Publications

Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH

 43
Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH

Tags:

Previous Article

Blood test can to identify cancer in patients with non-specific symptoms

Next Article

New drug candidate reverses metabolic liver disease and fibrosis

Related Posts

Targeting PKLR in liver diseases

Targeting PKLR in liver diseases

 113

Outer radial glia promotes white matter regeneration after neonatal brain injury

Outer radial glia promotes white matter regeneration af...

 118

TDP-43 dysfunction compromises UPF1-dependent mRNA metabolism in ALS

TDP-43 dysfunction compromises UPF1-dependent mRNA meta...

 31